Skip to content


Open Access

Adrenomedullin levels in patients with Familial Mediterranean Fever: a long term follow-up

  • Adem Polat1,
  • Celal Saglam1,
  • Yasemin Gulcan Kurt1,
  • Gökalp Başbozkurt1,
  • Betül Sözeri1,
  • İsmail Dursun1,
  • Özgür Kasapçopur1,
  • Harun Peru1,
  • Doğan Şimşek1,
  • Zübeyde Gündüz1,
  • Erbil Ünsal1,
  • Faysal Gök1,
  • Seza Özen1 and
  • Erkan Demirkaya1
Pediatric Rheumatology201412(Suppl 1):P242

Published: 17 September 2014


Pediatric PatientErythrocyte Sedimentation RateColchicineClinical VisitExpert Opinion


Familial Mediterranean Fever (FMF) is the most common periodic fever syndrome, characterized by recurrent fever and serositis attacks. It has been shown that there might be an ongoing subclinical inflammation between attacks. Adrenomedullin (ADM) is synthesized in endothelium, and has been shown to have high levels in patients with inflammation such as FMF. Colchicine is the treatment of choice and given once or twice daily depending on expert opinion.


In this study, it was aimed to investigate ADM as a marker for inflammation in pediatric patients with FMF who are using colchicine in different dosage schema.


Pediatric patients diagnosed with clinically and genetically confirmed FMF diagnosis were included in the study. The Colchicine was started in one or two doses randomly. The clinical and laboratory parameters were assessed on six clinical visits made every two months. After the third visit the dosing schema was changed to twice or once depending on the schema at the beginning.


A total of 37 patients were included in the study. Mean age of patients was 7.78±2.00 years, mean age at disease onset was 5.05 ± 3.04 years and mean age at diagnosis was 7.51 ± 2.66 years. Twenty patients received colchicine in once daily dosage while 17 patients had in twice daily dosage at the beginning of the study. There were 10 patients with heterozygote and 27 with homozygote MEFV mutations. After the treatment was started all patients demonstrated improvement in clinical and laboratory findings such as erythrocyte sedimentation rate and C-reactive protein. However, ADM levels did not show any correlation with ESR and CRP levels. Mean ADM levels in six consequtive visits were as follows, first 322.19±161.92 ng/L; second 330.50±189.63 ng/L; third 339.54±168.03 ng/L; forth 378.11±177.63 ng/L; fifth 328.91±172.30 ng/L and sixth 326.25±165.87 ng/L. ADM levels were similar in all visits (p=0.954) and did not show any difference between the first and second three visits i.e. before and after changing the dosage schema (p=0.593).


The results indicated that patients using colchicine in once or twice daily doses did not demonstrate any difference considering clinical and laboratory findings and had similar effects in controlling disease manifestations. ADM levels did not demonstrate any alterations in all visits which may suggest the continuation of subclinical inflammation in these patients.

Disclosure of interest

None declared.

Authors’ Affiliations

FAVOR, FMF Arthritis Vasculitis and Orphan Disease Research in Paediatric Rheumatology, Ankara, Turkey


© Polat et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.